Despite its potential, targeting LDHA comes with challenges:
1. Selectivity: Achieving selective inhibition of LDHA without affecting other isoforms of lactate dehydrogenase is crucial to minimize off-target effects. 2. Resistance: Cancer cells may develop resistance mechanisms to LDHA inhibitors, necessitating combination therapies to improve efficacy. 3. Toxicity: Inhibiting LDHA could affect normal tissues that rely on this enzyme for metabolic functions, leading to potential side effects.
